Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition

Abstract

Not available.

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model

“…Our study was performed in an in vitro culture model in which patient‐derived malignant cells were co‐cultured with healthy‐donor PBMCs as immune effector cells for ADCC or healthy‐donor serum for CDC [13]. Allogeneic effector cells and proteins were used to ensure the robustness and reproducibility of our assays.…”

“…Patient‐derived samples were cultured as described previously [13]. BMNCs were thawed and resuspended in RPMI 1640 GlutaMAX HEPES culture medium (Life Technologies), supplemented with 10% heat‐inactivated fetal bovine serum (Biowest), and 100μg/mL penicillin‐streptomycin (Gibco/Life Technologies).…”

Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma

“…Patient-derived MM cells were cultured in the presence of growth factors IL-6 and APRIL, which were shown to benefit survival of PCs ex vivo . 10 …”